Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery

1. Kim K, Hernlund E, Hernadi Z, Révész J, Pete I, Szánthó M, et al. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. Int J Gynecol Cancer 2013; 23(5):823-32.10.1097/IGC.0b013e318291e8caSearch in Google Scholar

2. André N, Banavali, S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? The Lancet Oncology 2013;14(6), e239-48.10.1016/S1470-2045(13)70056-1Search in Google Scholar

3. Lazić Z, Gajović O, Tanasković I, Milovanović D, Atanasijević D, Jakovljević, M. GOLD Stage Impact on COPD Direct Medical Costs in Elderly. Journal of Health Behavior and Public Health 2012; 2(3):1-7.Search in Google Scholar

4. Cupurdija, V., Lazic, Z., Petrovic, M., Mojsilovic, S., Cekerevac, I., Rancic, N., & Jakovljevic, M. (2015). Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity*, *. J Bras Pneumol, 41(1), 48-57.10.1590/S1806-37132015000100007435082525750674Search in Google Scholar

5. Jovanović M, Jakovljević M. Inpatient detoxification procedure and facilities: financing considerations from an Eastern European perspective. Alcohol and Alcoholism 2011; 46(3):364-5.10.1093/alcalc/agr01021330296Search in Google Scholar

6. Biorac N, Jakovljević M, Stefanović D, Perović S, Janković S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl 2009; 66(4):271-6.10.2298/VSP0904271BSearch in Google Scholar

7. Jakovljević M, Mijailović Z, Jovičić BP, Čanović P, Gajović O, Jovanović et al.. Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients. Hepat Mon 2013;19:13(6):e6750.10.5812/hepatmon.6750376820224032044Search in Google Scholar

8. Jakovljević M, Varjačić M, Janković SM. Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study. Value Health 2008;11(2):149-53.10.1111/j.1524-4733.2007.00222.x18380627Search in Google Scholar

9. Ranković A, Rančić N, Jovanovic M, Ivanovic M, Gajovic O, Lazic Z. et al. Impact of imaging diagnostics on the budget – Are we spending too much? Vojnosanit Pregl 2013; 70(7): 709–11.Search in Google Scholar

10. Jakovljević M, Ranković A, Rancic N, Jovanović M, Ivanović M, Gajović O, et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. Value in Health Regional Issues CEEWAA 2013;10.1016/j. vhri.2013.07.002.10.1016/j.vhri.2013.07.00229702868Search in Google Scholar

11. Jakovljevic, M., Gutzwiller, F., Schwenkglenks, M., Milovanovic, O., Rancic, N., Varjacic, M., ... & Matter-Walstra, K. (2014). Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19(3), 1111-1120.Search in Google Scholar

12. Jakovljević MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health economics and therapeutic pathways 2014;15(1):27-32.10.7175/fe.v15i1.909Search in Google Scholar

13. Jakovljević M., Jovanović M, Lazić Z, Jakovljević V, Đukić A, Veličković R et al. Current efforts and proposals to reduce healthcare costs in Serbia. Serbian Journal of Experimental and Clinical Research 2011;12(4):161-3.10.5937/sjecr1104161JSearch in Google Scholar

14. Kaló Z, Landa K, Doležal T, Vokó Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care 2012; 21(4): 442-9.10.1111/j.1365-2354.2012.01351.x22510226Search in Google Scholar

15. Jakovljević MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Economics: HEPAC: health economics in prevention and care. 2013; 14(2):153-9.10.1007/s10198-012-0439-y23143312Search in Google Scholar

16. Malik NN. Controlling the cost of innovative cancer therapeutics. Nature reviews. Clinical Oncology 2009;6(9):550-2.10.1038/nrclinonc.2009.11319707244Search in Google Scholar

17. Radovanović A, Dagović A, Jakovljević M. Economics of cancer related medical care: estimates worldwide and available domestic evidence. Archive of Oncology, 2011:19(3-4):59-63.10.2298/AOO1104059RSearch in Google Scholar

18. Nanda A, Nossikov A, Prokhorskas R, Shabanah MH Health in the central and eastern countries of the WHO European Region: an overview. World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales 1993; 46(3):158-65.Search in Google Scholar

19. Institute of public health of Serbia “Dr Milan Jovanovic Batut”. Department for Prevention and Control of Noncommunicable Diseases. Cancer incidence and mortality in central Serbia, Report No. XII (2012). http://www.batut.org.rs/download/publikacije/Registar%20za%20rak%20u%20Centralnoj%20Srbiji%202010.pdf (Accessed 30 August 2013)Search in Google Scholar

20. Institute of Public Health of Serbia, Belgrade “Dr Milan Jovanovic Batut” Health Statistical Yearbook of Republic of Serbia 2011. http://www.batut.org.rs/download/publikacije/pub2011.pdf(2012). (Accessed 30 August 2013)Search in Google Scholar

21. Chiesa F, Tradati N, Calabrese L, Gibelli B, Giugliano G, Paganelli G, et al. Thyroid disease in northern Italian children born around the time of the Chernobyl nuclear accident. Ann Oncol 2004; 15(12):1842-6.10.1093/annonc/mdh47715550591Search in Google Scholar

22. Papathanasiou K, Gianoulis C, Tolikas A, Dovas D, Koutsos J, Fragkedakis N, et al. Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neoplasia (CIN) and invasive cancer of the cervix in Greece. Clinical and Experimental Obstetrics & Gynecology 2005;32(1):58-60.Search in Google Scholar

23. Obradović M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. European journal of public health 2010; 20(4): 415-21.10.1093/eurpub/ckp20820624834Search in Google Scholar

24. Kovacevic A, Dragojevic-Simic V, Rancic N, Jurisevic M, Gutzwiller F, Matter-Walstra K, Jakovljevic M, End-of-life costs of medical care for advanced stage cancer patients, Vojnosanit Pregl 2015; 72(4): 1–10.10.2298/VSP1504334K26040179Search in Google Scholar

25. Bechev D. The Periphery of the periphery: the Western Balkans and the Euro Crisis. European Council on Foreign Relations, 2012.Search in Google Scholar

26. Panagiotou, Ritsa A. Effects of the global economic crisis on South-east Europe. Journal of Balkan and Near Eastern Studies 2010;12:187-94.10.1080/19448951003791849Search in Google Scholar

27. Stuckler, D., Basu, S., Suhrcke, M., Coutts, A., & McKee, M. (2009). The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. The Lancet, 374(9686), 315-323. Mazza R, Lina M, De Marco C, Pozzi P, Boffi R. Prevention and cancer care in Italy at the time of the world economic crisis. Epidemiol Prev 2013;37(4-5):193Search in Google Scholar

28. Jakovljevic M, Vukovic M, Antunović, M, Veličković R, Siladji Djendji A, Janković, et al. (Do policy measures impact cost consciousness of healthcare professionals? Value in Health 2013; 16(7): A542.10.1016/j.jval.2013.08.1376Search in Google Scholar

29. Kentikelenis, A., Karanikolos, M., Papanicolas, I., Basu, S., McKee, M., & Stuckler, D. (2011). Health effects of financial crisis: omens of a Greek tragedy. The Lancet, 378(9801), 1457-1458.Search in Google Scholar

30. Jakovljevic MB, Targeted immunotherapies overtaking emerging oncology market value based growth, forthcoming JBUON 2015; 20(1): 348-353.Search in Google Scholar

31. Motheral, B., Brooks, J., Clark, M.A., Crown, W.H., Davey, et al. A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases. Value in health. Journal of the International Society for Pharmacoeconomics and Outcomes Research 2003; 6(2):90-7.Search in Google Scholar

32. Puder KL, Wood LL, Sherrill A. Health economics with retrospective data: selection bias issues. The Journal of international medical research 1997; 25(1): 45-51.10.1177/0300060597025001079027673Search in Google Scholar

33. Medicines and Medicals Devices Agency of Serbia. Preparation of Professional Publications of the Agency. Belgrade, 2014. Available at: http://www.alims.gov.rs/eng/about-agency/publication/ (last accessed February 2014).Search in Google Scholar

34. Wild F. Increases in pharmaceutical expenditures of PHI by monoclonal antibodies. Versicherungsmedizin 2013; 65(2), 91-3.Search in Google Scholar

35. Jakovljević MB, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):181-94.10.1586/14737167.2014.881254Search in Google Scholar

36. Witteveen PO, van Groenestijn MA, Blijham GH, Schrijvers AJ. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol 1999; 10(2):161-5.10.1023/A:1008364401890Search in Google Scholar

37. Kovačević A, Tarabar D, Jakovljević M, Dragojević-Simić V. Colorectal carcinoma chemotherapy: current status and future directions, Pharmaca Serbica 2011;3(3-4):20-5.Search in Google Scholar

38. Viale PH, Grande C, Moore S. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clinical journal of oncology nursing, 2012;16(4):e133-141.10.1188/12.CJON.E133-E141Search in Google Scholar

39. The Republic Fund of Health Insurance. Republic of Serbia. http://www.eng.rfzo.rs Accessed 30 August 2013.Search in Google Scholar

40. Kolodziej M, Hoverman JR. Value-based reimbursement in oncology. Am J Manag Care 2012;18(3 Spec No.):SP124-6.Search in Google Scholar

41. Ward JC. Oncology reimbursement in the era of personalized medicine and big data. J Oncol Pract. 2014;10(2):83-6.10.1200/JOP.2014.001308Search in Google Scholar

42. Tanneberger S, Pannuti F, Mirri R, Panetta A, Mariano P, Giordani S, et al. Home hospital for advanced stage cancer patients: costs and benefits. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 1997; 91(2):117-23.Search in Google Scholar

43. Konstantinović D, Lazarević V, Milovanović V, Lapcević M, Konstantinović V, Vuković M. Financial sustainability of home care in the health system of the Republic of Serbia. Srp Arh Celok Lek 2013;141(3-4):214-8.10.2298/SARH1304214KSearch in Google Scholar

44. Gajić-Stevanović M, Teodorović N, Dimitrijević S, Jovanović D. Assessment of financial flow in the health system of Serbia in a period 2003-2006. Vojnosanit Pregl. 2010;67(5):397-402.10.2298/VSP1005397GSearch in Google Scholar

45. World Health Organization. Guide to producing national health accounts: with special applications for low-income and middle-income countries. 2003.Search in Google Scholar

46. Berman P. A. National health accounts in developing countries: appropriate methods and recent applications. Health Economics 1997; 6(1), 11-30.10.1002/(SICI)1099-1050(199701)6:1<11::AID-HEC238>3.0.CO;2-7Search in Google Scholar

47. Yamada, T., Chen, C. C., Yamada, T., Fahs, M., & Fukawa, T. (2006). Behavioral analysis of the choice of community-based formal home care, informal home care and nursing home care in Japan. The Geneva Papers on Risk and Insurance-Issues and Practice, 31(4), 600-632.10.1057/palgrave.gpp.2510101Search in Google Scholar

48. Barfar E, Rashidian A, Hosseini H, Nosratnejad S, Barooti E, Zendehdel K.Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women. Arch Iran Med. 2014;17(4):241-5.Search in Google Scholar

49. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87(6): 417-26.10.1093/jnci/87.6.417Search in Google Scholar

50. Zavras A, Andreopoulos N, Katsikeris N, Zavras D, Cartsos V, Vamvakidis A. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;2:1210.1186/1471-2458-2-12Search in Google Scholar

51. Macioch T, Hermanowski T. The indirect costs of cancer-related absenteeism in the workplace in Poland. Journal of occupational and environmental medicine 2011; 53(12):1472-7.10.1097/JOM.0b013e3182398dc7Search in Google Scholar

52. Macklis R, Lasher J. Palliative radiotherapy for skeletal metastases: cost-substitution analyses and economic impact. J Oncol Manag 1999;8(2):17-22.Search in Google Scholar

53. Larkin PJ, Dierckx de Casterlé B, Schotsmans P. Transition towards end of life in palliative care: an exploration of its meaning for advanced cancer patients in Europe. J Palliat Care 2007;23(2):69-79.10.1177/082585970702300202Search in Google Scholar

54. Jakovljevic M, Zugic A, Rankovic A, Dagovic A. Radiation Therapy Remains The Key Cost Driver Of Oncology Inpatient Treatment. J Med Econ. 2014 Sep 30:1-15. doi:10.3111/13696998.2014.971162.10.3111/13696998.2014.971162Search in Google Scholar

55. Barton MB, Gebski V, Manderson C, Langlands AO. Radiation therapy: are we getting value for money? Clinical oncology (Royal College of Radiologists (Great Britain1995; 7(5): 287-92.10.1016/S0936-6555(05)80535-7Search in Google Scholar

56. Van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? The Lancet Oncology 2012; 13(4): e169-77.10.1016/S1470-2045(11)70379-5Search in Google Scholar

57. Rescigno P, Imbevaro S, Jirillo A. The economic crisis and cancer chemotherapy: the role of the oncologist. Tumori 2012; 98(4): 532-3.10.1177/030089161209800420Search in Google Scholar

58. Zweifel P. The Grossman model after 40 years. The European journal of health economics : HEPAC : health economics in prevention and care, 2012; 13(6); 677-82.10.1007/s10198-012-0420-922955523Search in Google Scholar

59. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-50.10.1016/j.jval.2013.02.00223538175Search in Google Scholar

60. Uyl-de Groot CA. (2006) Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. Eur J Cancer; 42(17), 2862-6.10.1016/j.ejca.2006.08.00817008095Search in Google Scholar